Acadia Pharmaceuticals ACAD Change in AR
Change in AR at other companies
Other financials
Where this comes from
Reported directly by Acadia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.
The official record: Acadia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Acadia Pharmaceuticals's change in ar.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Acadia Pharmaceuticals's change in AR?
- Acadia Pharmaceuticals (ACAD) reported change in AR of $13.89M in Q1 2026.
- How has Acadia Pharmaceuticals's change in AR changed year-over-year?
- Acadia Pharmaceuticals's change in AR increased by 98.4% year-over-year, from $7M to $13.89M.
- What is the long-term trend for Acadia Pharmaceuticals's change in AR?
- Over 2 years (2023 to 2025), Acadia Pharmaceuticals's change in AR has grown at a -20.6% compound annual growth rate (CAGR), from $36.07M to $22.72M.
- What does change in AR mean?
- Increase or decrease in amounts owed by customers — the primary working capital driver for many businesses.